vs

Side-by-side financial comparison of Lucas GC Ltd (LGCL) and SUTRO BIOPHARMA, INC. (STRO). Click either name above to swap in a different company.

SUTRO BIOPHARMA, INC. is the larger business by last-quarter revenue ($11.6M vs $7.5M, roughly 1.6× Lucas GC Ltd).

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in Ja...

LGCL vs STRO — Head-to-Head

Bigger by revenue
STRO
STRO
1.6× larger
STRO
$11.6M
$7.5M
LGCL

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
LGCL
LGCL
STRO
STRO
Revenue
$7.5M
$11.6M
Net Profit
$414.1K
Gross Margin
33.7%
Operating Margin
4.0%
Net Margin
5.6%
Revenue YoY
-21.4%
Net Profit YoY
35.4%
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGCL
LGCL
STRO
STRO
Q4 25
$11.6M
Q3 25
$9.7M
Q2 25
$7.5M
$63.7M
Q1 25
$17.4M
Q4 24
$14.8M
Q3 24
$8.5M
Q2 24
$11.5M
$25.7M
Q1 24
$13.0M
Net Profit
LGCL
LGCL
STRO
STRO
Q4 25
Q3 25
$-56.9M
Q2 25
$414.1K
$-11.5M
Q1 25
$-76.0M
Q4 24
$-72.4M
Q3 24
$-48.8M
Q2 24
$1.0M
$-48.0M
Q1 24
$-58.2M
Gross Margin
LGCL
LGCL
STRO
STRO
Q4 25
Q3 25
Q2 25
33.7%
Q1 25
Q4 24
Q3 24
Q2 24
33.5%
Q1 24
Operating Margin
LGCL
LGCL
STRO
STRO
Q4 25
Q3 25
-499.9%
Q2 25
4.0%
-5.2%
Q1 25
-393.8%
Q4 24
-440.7%
Q3 24
-797.2%
Q2 24
8.8%
-189.4%
Q1 24
-435.0%
Net Margin
LGCL
LGCL
STRO
STRO
Q4 25
Q3 25
-586.6%
Q2 25
5.6%
-18.0%
Q1 25
-436.6%
Q4 24
-489.2%
Q3 24
-572.6%
Q2 24
8.9%
-186.8%
Q1 24
-447.5%
EPS (diluted)
LGCL
LGCL
STRO
STRO
Q4 25
Q3 25
$-0.67
Q2 25
$0.20
$-0.14
Q1 25
$-0.91
Q4 24
$-27.63
Q3 24
$-0.59
Q2 24
$0.01
$-0.59
Q1 24
$-0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGCL
LGCL
STRO
STRO
Cash + ST InvestmentsLiquidity on hand
$606.9K
$141.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.3M
$-132.5M
Total Assets
$8.8M
$173.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGCL
LGCL
STRO
STRO
Q4 25
$141.4M
Q3 25
$167.6M
Q2 25
$606.9K
$205.1M
Q1 25
$249.0M
Q4 24
$316.9M
Q3 24
$388.3M
Q2 24
$978.1K
$375.6M
Q1 24
$267.6M
Stockholders' Equity
LGCL
LGCL
STRO
STRO
Q4 25
$-132.5M
Q3 25
$-87.3M
Q2 25
$6.3M
$-32.1M
Q1 25
$-25.8M
Q4 24
$44.6M
Q3 24
$111.2M
Q2 24
$5.3M
$152.2M
Q1 24
$98.0M
Total Assets
LGCL
LGCL
STRO
STRO
Q4 25
$173.8M
Q3 25
$209.7M
Q2 25
$8.8M
$262.4M
Q1 25
$321.4M
Q4 24
$387.2M
Q3 24
$451.8M
Q2 24
$7.8M
$489.0M
Q1 24
$403.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGCL
LGCL
STRO
STRO
Operating Cash FlowLast quarter
$-177.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGCL
LGCL
STRO
STRO
Q4 25
$-177.2M
Q3 25
$-38.2M
Q2 25
$-44.7M
Q1 25
$-67.9M
Q4 24
$-71.7M
Q3 24
$-64.5M
Q2 24
$9.5M
Q1 24
$-64.7M

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGCL
LGCL

Recruitment service$4.4M60%
Others$2.9M39%

STRO
STRO

Segment breakdown not available.

Related Comparisons